SPYRE THERAPEUTICS INC

Spyre Therapeutics CFO buys 15,000 shares at $87.89, signaling bullish confidence amid a buy‑sell‑buy rhythm that highlights strategic insider trading and potential upside for investors.

Fairmount’s 16,667‑share preferred conversion into 666,680 common shares boosts its 6% stake in Spyre, signalling confidence in the biotech’s ulcerative colitis pipeline.

Insider sale by Spyre Therapeutics’ Michael Henderson: a 20k‑share 10b5‑1 move amid a 500% stock surge—what it signals for investors.

Insightful insider trade by Sloan Sheldon at Spyre Therapeutics signals cautious optimism, with buying aligned to a new Paragon license and positive market sentiment.

Fairmount’s new option grant for Spyre Therapeutics signals confidence in its drug pipeline and hints at a 2027 upside—what investors should watch.

Spyre CFO’s $14.50 buy at 12.5k shares signals confidence; insider discipline and a 52‑week high suggest bullish prospects for IBD therapy.

Spyre Therapeutics’ CEO sells 14,999 shares under a 10b5‑1 plan – steady insider selling, not a red flag. Learn how this affects price, investor sentiment and future pipeline prospects.

CEO Turtle Cameron’s March 2026 Spyre Therapeutics stock sale offers investors insight into insider liquidity strategy amid the company’s near‑term outlook.

Spyre CFO’s new 140k stock options show long‑term confidence—explore how insider moves align with upcoming POC milestones and investor upside.